DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fecal dipeptidyl peptidase-4 may be used as a ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors ...

Findings from a study published in Acta Diabetologica support that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with better vitamin D balance in patients with type 2 diabetes ...

The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure in patients with type 2 diabetes is uncertain, based on low quality of evidence found in a systematic review and ...

FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain. The ...